Skip to main content Skip to search Skip to main navigation

EMA: Use of CTIS mandatory in the EU

As we already reported in December 2022, the use of the Clinical Trials Information System (CTIS) is now obligatory in the EU.

Since January 31, CTIS has been the single access point for sponsors and regulators of primary clinical trials when it comes to submitting and assessing clinical trial data.

This follows a one-year transition period during which sponsors had the choice of whether to apply for a new clinical trial in the EU or EEA under the Clinical Trials Directive or according to the new Clinical Trials Regulation (CTR).

In the past, sponsors had to submit clinical trial applications separately to national competent authorities and ethics committees in each country.

But with CTIS, sponsors will now be able to apply for approvals in up to 30 EU/EEA countries at the same time and with the same submission documents.

By the end of January 2025, all ongoing trials approved under the Clinical Trials Directive 2001/20/EC will fall into the new regulation and will have to be transferred to CTIS.


Source:

EMA: CTIS

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ICH: Updated Q9(R1) Briefing Pack

ICH: Updated Q9(R1) Briefing Pack

The ICH has fully revised the Q9(R1) Briefing Pack (March/April 2026) to align with the updated ICH Q9 guideline.
Read more
EMA: New Plans for the EU GMP Guide

EMA: New Plans for the EU GMP Guide

EMA published the GMDP Inspectors Working Group’s new 2026-2028 work plan and its 2025 annual report.
Read more
EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA launched a pilot under which EEA GMP inspectors will assess how sites demonstrate the effectiveness of their pharmaceutical quality system for risk-based change management, and whether the EEA GMP certificate could serve as the main evidence of this effectiveness.
Read more
EMA: Updated Guideline on Active Substance Chemistry

EMA: Updated Guideline on Active Substance Chemistry

The EMA has updated guidance on the information required for the manufacture and control of active substances used in medicinal products, with a 1 September 2026 date of application.
Read more
EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA added a new GMP/Q&A section on its website and published a dedicated Q&A document on 3D printing (3DP) for solid oral dosage forms.
Read more
Microbiological Monitoring – Sources of Contamination

Microbiological Monitoring – Sources of Contamination

All pharmaceutical dosage forms must be manufactured under controlled microbiological conditions. This requires microbial monitoring. This applies not only to sterile manufacturing, but also to facilities that manufacture non-sterile products.
Read more
Previous
Next